Tiziana Life Sciences (TLSA) Projected to Announce Quarterly Earnings on Friday

Tiziana Life Sciences (NASDAQ:TLSA) is projected to release its results before the market opens on Friday, September 18th. Analysts expect the company to announce earnings of ($0.0783) per share for the quarter.

Tiziana Life Sciences Trading Down 4.3%

Shares of TLSA stock opened at $0.85 on Wednesday. Tiziana Life Sciences has a 1-year low of $0.81 and a 1-year high of $2.35. The stock’s fifty day simple moving average is $1.04 and its 200-day simple moving average is $1.21.

Insiders Place Their Bets

In other news, CEO Ivor Elrifi bought 667,000 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $1.00 per share, with a total value of $667,000.00. Following the transaction, the chief executive officer directly owned 4,472,261 shares in the company, valued at approximately $4,472,261. This trade represents a 17.53% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders bought 988,423 shares of company stock valued at $985,909. Corporate insiders own 39.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TLSA. Weiss Ratings reissued a “sell (e+)” rating on shares of Tiziana Life Sciences in a research note on Wednesday, August 26th. Zacks Research upgraded Tiziana Life Sciences to a “hold” rating in a report on Tuesday, July 14th. Finally, BTIG Research started coverage on Tiziana Life Sciences in a report on Thursday, September 3rd. They issued a “buy” rating on the stock. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold”.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small?molecule program, milciclib, is an oral cyclin?dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.